India’s $50 billion pharmaceutical sector — the world’s largest producer of generic medicines — is coming under strain as the Iran conflict pushes up energy costs and disrupts trade routes. The industry supplies about 20% of global generic volumes, sends more than half of its exports to tightly regulated markets such as the US and EU, and accounts for nearly half of generic prescriptions filled in the United States, making any supply shock globally significant.
The central vulnerability is heavy reliance on imported active pharmaceutical ingredients (APIs). Some 60–70% of APIs used by Indian manufacturers are sourced from China. Rising oil prices linked to the conflict have lifted freight rates and increased the cost of petroleum-derived chemical solvents used in drug manufacture, raising the cost base even for staples such as metformin and paracetamol. Input price spikes for methanol and isopropyl alcohol, higher packaging costs, logistics delays, and insurance surcharges tied to conflict risk have all added to producers’ burdens.
Industry executives say many firms are cushioned by two to three months of inventory, but that buffer may be insufficient if resupplies remain uncertain. Several plants have also faced energy-related shutdowns; restarting production can take weeks. SynCore director Javin Bhinde said the disruption has exposed the fragility of the pharma supply chain and warned that if pressures persist into the summer, ‘the real impact could begin from June.’ Estimates from industry sources put immediate disruption costs to Indian drugmakers at roughly $300 million to $500 million, with the potential for larger losses if shipping problems continue.
Government and industry responses so far have been short-term: waiving import duties on key inputs, permitting limited price increases on essential medicines, and urging firms to diversify sourcing and boost domestic production. Commerce Secretary Rajesh Agrawal warned that a prolonged conflict could hurt exports beyond the Middle East and pressed the sector to reduce import dependence. But building new domestic API capacity takes years, and local production can be 20–25% more expensive — a ‘sovereignty premium’ many smaller manufacturers cannot absorb under thin margins and strict price controls.
Experts note that risks vary by product. Chronic-use oral medicines can be sustained for a few months with stockpiles, while cold-chain products such as vaccines and injectables are immediately vulnerable. Less visible pressures — longer rerouted shipping adding up to two weeks in transit, higher insurance and container costs, and capital tied up in excess inventory — could amplify shortages and cost increases. Former WHO chief scientist Soumya Swaminathan warned that continued disruption could lead to rising costs or even global shortages and urged early coordination with major purchasers such as WHO, UNICEF and Gavi, citing the cross-border cooperation used during the COVID-19 vaccine response by manufacturers like the Serum Institute of India and Bharat Biotech.
As the industry manages higher energy bills and seeks strategic reserves, the immediate task is keeping plants running while planning long-term measures to reduce import dependence and shore up supply resilience.